Source disclosure: February 19, 2026
Cuorips Inc. [4894.T]
TOKYO, Feb 19 (Pulse News Wire) – Cuorips Inc. (4894.T) announced today that its human induced pluripotent stem cell-derived cardiac muscle sheet product, IPSOC-1, received conditional approval from the Pharmaceutical Affairs Council's Regenerative Medicine Subcommittee.
The council determined that the product could be approved with conditions and deadlines attached, aimed at treating severe heart failure caused by ischemic cardiomyopathy unresponsive to conventional treatments. The company had previously disclosed on February 13 that the subcommittee would review the manufacturing and marketing approval of IPSOC-1 along with potential conditions and timelines. Today’s decision paves the way for a formal conditional approval by the Ministry of Health, Labour and Welfare.
IPSOC-1 is designed to treat patients whose condition does not improve with existing therapies. It involves transplanting sheets of cardiac muscle cells derived from human iPSCs onto the heart. The product was designated as a regenerative medical product for rare diseases on October 24, 2025 (designation number: (R7)37).
While the impact on the current fiscal period is expected to be minor, Cuorips stated it will promptly disclose any significant developments related to this matter.
AI-translated content. 🟢 Confidence: High See terms • Original filing